Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5831 |
Name | fallopian tube endometrioid adenocarcinoma |
Definition | A fallopian tube adenocarcinoma that derives_from endometrial epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | DOID:1972 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer fallopian tube cancer fallopian tube carcinoma fallopian tube adenocarcinoma fallopian tube endometrioid adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02345265 | Phase II | Cediranib + Olaparib | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02364713 | Phase II | Pegylated liposomal doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Gemcitabine | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02446600 | Phase III | Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 2 |
NCT03206645 | Phase I | Carboplatin + Paclitaxel + Unesbulin | PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy | Completed | USA | 0 |
NCT03278717 | Phase III | Olaparib Cediranib + Olaparib | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (ICON9) | Unknown status | NZL | GBR | CAN | AUS | 0 |
NCT04598321 | Phase I | Talazoparib | BrUOG 390: Neoadjuvant Treatment With Talazoparib | Terminated | USA | 0 |
NCT05397093 | Phase I | ITIL-306 | ITIL-306 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT06433219 | Phase II | M1774 + Niraparib M1774 + M4076 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | Recruiting | USA | 0 |
NCT06618235 | Phase Ib/II | THEO-260 | Trial of THEO-260 in Ovarian Cancer Patients (OCTOPOD) | Recruiting | GBR | 0 |